Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11512164 | 1.00 | CYP1A2 (0.44) | CYP1A2KMT2AGAAALDH1A1TDP1 | |
| SCHEMBL5094619 | 0.92 | KMT2A (0.41) | CYP1A2KMT2AGAAALDH1A1TDP1 | |
| SCHEMBL3828967 | 0.92 | KMT2A (0.41) | CYP1A2KMT2AGAAALDH1A1TDP1 | |
| SCHEMBL11614930 | 0.92 | KMT2A (0.41) | CYP1A2KMT2AGAAALDH1A1TDP1 | |
| SCHEMBL3822316 | 0.91 | CYP1A2 (0.42) | CYP1A2KMT2AGAAALDH1A1TDP1 | |
| SCHEMBL3813428 | 0.90 | DGKA (0.44) | CYP1A2KMT2AALDH1A1TDP1CYP3A4 | |
| SCHEMBL3823229 | 0.86 | CYP1A2 (0.43) | CYP1A2KMT2AGAAALDH1A1TDP1 | |
| SCHEMBL28570515 | 0.86 | KMT2A (0.43) | CYP1A2KMT2AGAAALDH1A1TDP1 | |
| SCHEMBL28693793 | 0.86 | KMT2A (0.43) | CYP1A2KMT2AGAAALDH1A1TDP1 | |
| SCHEMBL3828853 | 0.86 | CYP1A2 (0.38) | CYP1A2KMT2AGAAALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1231919-B1 | Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors | SLOAN KETTERING INST CANCER (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8110577-B2 | Histone deacetylase inhibitors | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-02-07 | — | — | US | disclosed |
| US-8110577-B2 | Histone deacetylase inhibitors | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-02-07 | — | — | US | disclosed |
| US-8110577-B2 | Histone deacetylase inhibitors | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2012-02-07 | — | — | US | disclosed |
| US-20100160392-A1 | HISTONE DEACETYLASE INHIBITORS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160392-A1 | HISTONE DEACETYLASE INHIBITORS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160392-A1 | HISTONE DEACETYLASE INHIBITORS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2010-06-24 | — | — | US | disclosed |
| WO-2009107785-A1 | MARKER FOR DETECTION OF IL-17-PRODUCING HELPER T-CELL, AND METHOD FOR DETECTION OF IL-17-PRODUCING HELPER T-CELL | シスメックス株式会社 (JP) | 2009-09-03 | — | — | WO | disclosed |
| EP-2086950-A2 | HISTONE DEACETYLASE INHIBITORS | Queen Mary and Westfield College (GB) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008047138-A2 | HISTONE DEACETYLASE INHIBITORS | QUEEN MARY AND WESTFIELD COLLEGE (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-26 | — | — | US | disclosed |
| US-7126001-B2 | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-01 | — | — | US | disclosed |
| US-6511990-B1 | Selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-01-28 | — | — | US | disclosed |
| CN-1378450-A | Novel class of cytodifferentiating agents and histone deactylase inhibitors, and methods of use thereof | SLOAN KETTERING INST OF CANCER (US) | 2002-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | CYP1A2 2842/4885KMT2A 153/4885GAA 1318/4885 |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | CYP1A2 2842/4885KMT2A 153/4885GAA 1318/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | CYP1A2 2842/4885KMT2A 153/4885GAA 1318/4885 |
| US-20100160392-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | CYP1A2 3465/4885KMT2A 107/4885GAA 3800/4885 |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | CYP1A2 2786/4885KMT2A 173/4885GAA 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.